Funding for this research was provided by:
Asia Diabetes Foundation
Received: 11 January 2022
Accepted: 31 May 2022
First Online: 14 July 2022
: The assessment was performed during one of the clinic visits. Written informed consent was obtained from all patients to allow use of anonymized data for analysis and publication purposes. The study was approved by the Joint CUHK-New Territories East Cluster Clinical Research Ethics Committee and local institutional ethics committee of each participating site (CREC Reference Number: 2007.339). This study was conducted in accordance with the Declaration of Helsinki.
: Not applicable
: Juliana CN Chan is the Chief Executive Officer (pro-bono) and board member of the Asia Diabetes Foundation, a charitable organization governed by the Chinese University of Hong Kong (CUHK) Foundation. The other authors declare that they have no competing interests.